home / stock / ngenf / ngenf news


NGENF News and Press, NervGen Pharma Corp From 02/21/24

Stock Information

Company Name: NervGen Pharma Corp
Stock Symbol: NGENF
Market: OTC
Website: nervgen.com

Menu

NGENF NGENF Quote NGENF Short NGENF News NGENF Articles NGENF Message Board
Get NGENF Alerts

News, Short Squeeze, Breakout and More Instantly...

NGENF - NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 20...

NGENF - NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

On track to complete enrollment of the chronic cohort in Q2 2024 Data readout from chronic cohort expected in Q3 2024 Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - ...

NGENF - NervGen Pharma GAAP EPS of -$0.07

2023-11-09 12:04:00 ET More on NervGen Pharma Historical earnings data for NervGen Pharma Financial information for NervGen Pharma For further details see: NervGen Pharma GAAP EPS of -$0.07

NGENF - NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates

Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Seasoned financial industry execut...

NGENF - Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki

Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech compan...

NGENF - NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected in Mid-2024 Vancouver, British Columbia--(Newsfile Corp. - October 23, 2023) -   NervGe...

NGENF - NervGen Pharma Appoints John Ruffolo to Board of Directors

Extensive experience in private equity, venture capital and advising high growth, innovative companies Brings personal experience and knowledge of spinal cord injury to NervGen's board Important board addition joins as Company advances clinical milestone with Phase 1b/2a study of NVG-291 under...

NGENF - NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech compa...

NGENF - NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF)  ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that...

NGENF - NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, w...

Previous 10 Next 10